Bluebird Bio Sold to Carlyle and SK Capital for $3 per Share
Gene therapy developer Bluebird Bio has sold itself to private equity firms Carlyle and SK Capital in a deal worth $68 million, with the option to pay an additional $96 million if sales of its gene therapies reach $600 million by 2027. The company’s share price plummeted from $2,300 to just $3 per share over … Read more